Period Prevalence of Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome
Publication date: Available online 30 October 2026 Source: AACE Endocrinology and Diabetes Author(s): Frances Ann C. Yap, Maria Honolina S. Gomez, Jo Rocel Z. Lacson, Ma. Felisse Carmen Gomez-Tuazon
Period Prevalence of Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome. // Academic Pediatrics. – URL: https://www.sciencedirect.com/science/article/pii/S3050915726002730?dgcid=rss_sd_all
Period Prevalence of Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome. Academic Pediatrics. https://www.sciencedirect.com/science/article/pii/S3050915726002730?dgcid=rss_sd_all
“Period Prevalence of Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome.” Academic Pediatrics.
@article{article2361,
title = {Period Prevalence of Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome},
journal = {Academic Pediatrics},
url = {https://www.sciencedirect.com/science/article/pii/S3050915726002730?dgcid=rss_sd_all}
}
Publication date: Available online 14 November 2026 Source: AACE Endocrinology and Diabetes Author(s): Laura Pierotti, Chiara Sardella, Simone Della Valentina, Anna Dal Lago, Giacomo De Leo, Filomena Cetani